Anixa Biosciences (NASDAQ:ANIX) CEO Amit Kumar Purchases 8,000 Shares of Company Stock

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar acquired 8,000 shares of the company’s stock in a transaction that occurred on Thursday, October 22nd. The shares were bought at an average price of $2.72 per share, for a total transaction of $21,760.00. Following the completion of the acquisition, the chief executive officer owned 680,000 shares of the company’s stock, valued at $1,849,600. This trade represents a 1.19% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Amit Kumar also recently made the following trade(s):

• On Thursday, September 24th, Amit Kumar bought 7,000 shares of Anixa Biosciences stock. The stock was bought at an average cost of $2.78 per share, with a total value of $19,460.00.
• On Thursday, September 10th, Amit Kumar bought 3,000 shares of Anixa Biosciences stock. The stock was bought at an average cost of $2.75 per share, with a total value of $8,250.00.
• On Thursday, September 10th, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The shares were purchased at an average price of $2.76 per share, with a total value of $13,800.00.
• On Friday, July 31st, Amit Kumar bought 5,000 shares of Anixa Biosciences stock. The shares were purchased at an average price of $3.47 per share, with a total value of $17,350.00.
• On Friday, July 24th, Amit Kumar purchased 3,000 shares of Anixa Biosciences stock. The stock was purchased at an average cost of $3.73 per share, for a total transaction of $11,190.00.
• On Monday, July 27th, Amit Kumar purchased 3,188 shares of Anixa Biosciences stock. The stock was purchased at an average cost of $3.37 per share, for a total transaction of $10,743.56.
• On Monday, July 27th, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The stock was purchased at an average price of $3.44 per share, for a total transaction of $17,200.00.

Anixa Biosciences Price Performance

Shares of Anixa Biosciences stock opened at $2.78 on Friday. The firm has a market cap of $96.63 million, a price-to-earnings ratio of -8.69 and a beta of 0.47. The stock’s 50-day moving average is $3.00 and its 200-day moving average is $2.98. Anixa Biosciences Inc has a one year low of $2.32 and a one year high of $5.46.

Anixa Biosciences (NASDAQ:ANIX) last posted its quarterly earnings data on Wednesday, September 9th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.08). On average, equities analysts expect that Anixa Biosciences Inc will post -0.31 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ANIX shares. HC Wainwright reduced their price target on Anixa Biosciences from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Tuesday, September 22nd. Zacks Research cut shares of Anixa Biosciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a research report on Tuesday, June 30th. Citigroup reaffirmed a “buy” rating on shares of Anixa Biosciences in a research report on Tuesday, October 6th. Finally, Weiss Ratings upgraded shares of Anixa Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, September 17th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $8.00.

Institutional Trading of Anixa Biosciences

Several institutional investors and hedge funds have recently bought and sold shares of ANIX. CoreCap Advisors LLC boosted its position in Anixa Biosciences by 19.2% during the third quarter. CoreCap Advisors LLC now owns 62,020 shares of the company’s stock valued at $182,000 after purchasing an additional 10,000 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in Anixa Biosciences in the second quarter valued at approximately $30,000. Corient Private Wealth LP grew its stake in Anixa Biosciences by 87.0% in the second quarter. Corient Private Wealth LP now owns 37,400 shares of the company’s stock valued at $105,000 after purchasing an additional 17,400 shares in the last quarter. AXQ Capital LP bought a new position in Anixa Biosciences in the second quarter valued at approximately $41,000. Finally, Canada Pension Plan Investment Board bought a new position in Anixa Biosciences in the second quarter valued at approximately $38,000. Institutional investors own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences, Inc is a clinical-stage biotechnology company focused on developing immunotherapies and vaccines for cancer and infectious diseases. Rather than marketing a broad portfolio of commercial products, the company concentrates on advancing novel therapies through research collaborations and clinical development.

Anixa’s cancer programs include a breast cancer vaccine intended to target alpha-lactalbumin, a protein associated with certain breast cancers. The program is being developed in collaboration with researchers at Cleveland Clinic.